510(k) Sponsors Should Be Wary Of Informal Talk With FDA, Attorney Says
This article was originally published in The Gray Sheet
Executive Summary
Informal communications via telephone or e-mail before or during a 510(k) submission can be an efficient approach for sponsors, but companies should be aware of the pitfalls, says Hogan & Hartson Partner and FDA device specialist John Smith